What is the difference between azivudine, monogravir and nematvir/ritonavir?💫💫💫

Azivudine, monogravir and nematvir/ritonavir are all clinical drugs used to treat the new coronavirus. What's the difference between them? What is the anti-coronavirus mechanism?The new coronavirus is composed of RNA and protein. The raw material for RNA synthesis is cytosine nucleoside. Azivudine and monogravir are cytosine nucleoside analogs. They will synthesize poor...

Read More

The impact of COVID-19 pneumonia on children may be seriously underestimated👪👪👪

Long-term symptoms of COVID-19 refer to a series of symptoms appearing after infection with COVID-19, including organ inflammation, shortness of breath, fatigue, behavior changes and so on. Studies have shown that about 30% of people infected with the COVID-19 will have long-term symptoms, even though most people can recover quickly. A recent study in the United...

Read More

The COVID-19 epidemic is far from over😷😷😷

Recently, the counter-attack of COVID-19 epidemic will cause schools to be forced to close and classes to be suspended. People received the COVID-19 vaccine will still face a new round of infection. When the hospital is overwhelmed again, office workers will also weigh whether they need to continue working at home. Scientists believe that before the end of COVID-19...

Read More

Inventory of various new discoveries of metformin😎😎😎

Metformin is an anti-diabetic drug and a classic oral hypoglycemic agent. Since its inception in 1957, it has been used clinically for more than 60 years. It is currently one of the most widely used oral hypoglycemic drugs in the world. Even though there are many new hypoglycemic drugs, metformin is still the primary drug for type 2 diabetes.Metformin was born in 1929...

Read More

Is the COVID-19 drug better than vaccine??? 😲😲😲

On October 1st, Merck and Ridgeback Biotherapeutics reported the results from their COVID-19 drug Molnupiravir from phase 3 study in patients with mild to moderate COVID-19. In their study, the risk of hospitalization or death are reduced by about 50%. Only 7.3% patients who got Molnupiravir were either hospitalized or died during the research. And the placebo group is 14.1%. The Molnupiravir group is no one dead and the placebo group is reported...

Read More